Recent advancements in the field of diabetes treatment have brought about a novel class of medications known as GLP-1 and GIP receptor agonists. These agents offer a unique mechanism of action by activating the receptors for both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This dual strategy leads to enha